<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970943</url>
  </required_header>
  <id_info>
    <org_study_id>AT007530-01</org_study_id>
    <secondary_id>R21AT007530-01</secondary_id>
    <nct_id>NCT01970943</nct_id>
  </id_info>
  <brief_title>Molecular and Functional PET-fMRI Measures of Analgesia in Migraine</brief_title>
  <official_title>Molecular and Functional PET-fMRI Measures of Analgesia in Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Alternative Medicine (NCCAM)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The placebo effect is a phenomenon that has experienced major advances of its understanding
      in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have
      yet to be compared to healthy subjects.  The investigators study aims to investigate the
      magnitude of placebo response and related opioid release in patients that suffer from
      episodic migraines as compared to healthy controls. In particular, the investigators are
      looking to map brain activity during placebo analgesia using modern brain imaging techniques
      such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET).
      The investigators hypothesis is that placebo response and the availability of opioid
      receptors is reduced in chronic migraine patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>VAS Pain rating</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>This study will investigate how placebo may reduce experimental pain induced by contact heat.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD signal</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional Magnetic Resonance Imaging Blood Oxygenation Level Dependent Signal will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET Diprenorphine</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positron Emission Tomography with C11 diprenorphine will be used to measure opioid receptors</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Migraine</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>PET-fMRI investigation on healthy subjects and patients with migraine.  No drug condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be compared to No Intervention.</description>
    <arm_group_label>Saline Injection (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Migraine patients with aura with acute episodic migraine meeting the IHS
             Classification ICHD-II criteria, 3-14 migraines per month.

          -  History of episodic migraine for at least 3 years

          -  Ages 21-50

          -  Male or Female

          -  Right Handed

        Matched healthy subjects will also be recruited.

        Exclusion Criteria:

          -  Other significant disease (systemic or CNS)

          -  Pregnancy

          -  Claustrophobia

          -  Weight &gt;235 lbs (limit of MRI table)

          -  Significant drug including alcohol history (&gt; 7 glasses of alcohol per week)

          -  Beck Depression Inventory II (BDI-II) score &gt; 25 (moderate to severe depression)

          -  Any metal implants incompatible with MRI (including dental bridges, crowns,
             retainers, orthodontic devices e.g. braces, IUDs, aneurysm clips or other devices,
             tattoos containing metallic ink, cardiac pacemakers, prosthetic hear valves, other
             prostheses, neurostimulator devices, implanted infusion pumps, exposure to shrapnel
             or metal filings, cochlear implants, etc.)

          -  Previous significant research related exposure to ionizing radiation.

          -  History of allergy or adverse reaction to opioids

          -  Significant medical history of such as seizure disorder, diabetes, alcoholism,
             cardiac disease including coronary artery disease, psychiatric problems; drug
             addiction, respiratory problems, liver disease, etc.

          -  Positive drug of abuse screen (excluding medications currently prescribed for their
             clinical condition, e.g. opioids, benzodiazepines, etc.)

          -  Patients with migraine &lt;72 hours prior to the experiments will not be included to
             ensure inter-ictal state.

          -  Opioids or preventative medication such as topiramate, SSRIs etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Borsook, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clas Linnman, Ph.D</last_name>
    <phone>857-284-2816</phone>
    <email>clas.linnman@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihayl P Petkov, BA</last_name>
    <phone>2072663329</phone>
    <email>mihayl.petkov@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Athinoula A. Martinos. Center for Biomedical Imaging</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clas Linnman, PhD</last_name>
      <phone>857-284-2816</phone>
      <email>clas.linnman@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Borsook, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lino Becerra, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward George, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacob Hooker, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clas Linnman, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>David Borsook</investigator_full_name>
    <investigator_title>David Borosook, MD</investigator_title>
  </responsible_party>
  <keyword>migraine, headache, episodic, chronic, pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
